Aigen Investment Management LP Has $223,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Aigen Investment Management LP decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 58.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 985 shares of the medical instruments supplier’s stock after selling 1,377 shares during the period. Aigen Investment Management LP’s holdings in Becton, Dickinson and Company were worth $223,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tompkins Financial Corp grew its stake in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Wesbanco Bank Inc. lifted its holdings in Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after buying an additional 48 shares in the last quarter. S.A. Mason LLC boosted its position in Becton, Dickinson and Company by 3.7% in the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after buying an additional 50 shares during the last quarter. Americana Partners LLC increased its stake in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after buying an additional 52 shares during the period. Finally, Novare Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 5.2% during the fourth quarter. Novare Capital Management LLC now owns 1,110 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $229.51 on Monday. The stock has a market cap of $65.90 billion, a PE ratio of 38.12, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The stock has a 50-day moving average of $232.98 and a 200-day moving average of $232.71. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.81%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent research reports. Barclays raised their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $278.29.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson acquired 1,500 shares of the stock in a transaction dated Monday, February 10th. The stock was bought at an average price of $233.62 per share, with a total value of $350,430.00. Following the completion of the transaction, the director now directly owns 8,015 shares of the company’s stock, valued at approximately $1,872,464.30. The trade was a 23.02 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,423 shares of company stock worth $1,239,780. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.